Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Patients
2.2. Imaging
2.3. Image and Data Analysis
2.4. Statistical Analysis
3. Results
3.1. Spatial Heterogeneity in Local Growth Dynamics
3.2. Predictive Value of Focal Lesion Size and Growth Dynamic and Diffuse Infiltration Score
3.3. Correlation of Focal Lesion Size and Growth Dynamic with Presence/Appearance of Corresponding Osteolytic Lesions in CT Imaging
3.4. Correlation of Diffuse Infiltration with Decrease in Hemoglobin
4. Discussion
4.1. Spatial Heterogeneity in Growth Dynamics between Different Focal Lesions
4.2. Predictive Value of FL Characteristics and Quantification of Diffuse Infiltration
4.3. Connection between MRI Findings and Clinical Progression Patterns
4.4. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Neben, K.; Jauch, A.; Hielscher, T.; Hillengass, J.; Lehners, N.; Seckinger, A.; Granzow, M.; Raab, M.S.; Ho, A.D.; Goldschmidt, H.; et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Clin. Oncol. 2013, 31, 4325–4332. [Google Scholar] [CrossRef]
- Fonseca, R.; Bergsagel, P.L.; Drach, J.; Shaughnessy, J.; Gutierrez, N.; Stewart, A.K.; Morgan, G.; Van Ness, B.; Chesi, M.; Minvielle, S.; et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia 2009, 23, 2210–2221. [Google Scholar] [CrossRef] [Green Version]
- Rasche, L.; Chavan, S.S.; Stephens, O.W.; Patel, P.H.; Tytarenko, R.; Ashby, C.; Bauer, M.; Stein, C.; Deshpande, S.; Wardell, C.; et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun. 2017, 8, 268. [Google Scholar] [CrossRef] [PubMed]
- Kyle, R.A.; Remstein, E.D.; Therneau, T.M.; Dispenzieri, A.; Kurtin, P.J.; Hodnefield, J.M.; Larson, D.R.; Plevak, M.F.; Jelinek, D.F.; Fonseca, R.; et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. N. Engl. J. Med. 2007, 356, 2582–2590. [Google Scholar] [CrossRef] [PubMed]
- Hillengass, J.; Fechtner, K.; Weber, M.-A.; Bäuerle, T.; Ayyaz, S.; Heiss, C.; Hielscher, T.; Moehler, T.M.; Egerer, G.; Neben, K.; et al. Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma. J. Clin. Oncol. 2010, 28, 1606–1610. [Google Scholar] [CrossRef]
- Hillengass, J.; Weber, M.A.; Kilk, K.; Listl, K.; Wagner-Gund, B.; Hillengass, M.; Hielscher, T.; Farid, A.; Neben, K.; Delorme, S.; et al. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 2014, 28, 174–178. [Google Scholar] [CrossRef]
- Kastritis, E.; Moulopoulos, L.A.; Terpos, E.; Koutoulidis, V.; Dimopoulos, M.A. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic ( smoldering ) multiple myeloma. Leukemia 2014, 28, 2402–2403. [Google Scholar] [CrossRef]
- Dhodapkar, M.V.; Sexton, R.; Waheed, S.; Usmani, S.; Papanikolaou, X.; Nair, B.; Petty, N.; Shaughnessy, J.D.J.; Hoering, A.; Crowley, J.; et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014, 123, 78–85. [Google Scholar] [CrossRef] [Green Version]
- Dispenzieri, A.; Kyle, R.A.; Katzmann, J.A.; Therneau, T.M.; Larson, D.; Benson, J.; Clark, R.J.; Melton, L.J.; Gertz, M.A.; Kumar, S.K.; et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008, 111, 785–789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kastritis, E.; Terpos, E.; Moulopoulos, L.; Spyropoulou-Vlachou, M.; Kanellias, N.; Eleftherakis-Papaiakovou, E.; Gkotzamanidou, M.; Migkou, M.; Gavriatopoulou, M.; Roussou, M.; et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013, 27, 947–953. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsen, J.T.; Kumar, S.K.; Dispenzieri, A.; Kyle, R.A.; Katzmann, J.A.; Rajkumar, S.V. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013, 27, 941–946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Waxman, A.J.; Mick, R.; Garfall, A.L.; Cohen, A.; Vogl, D.T.; Stadtmauer, E.A.; Weiss, B.M. Classifying ultra-high risk smoldering myeloma. Leukemia 2015, 29, 751–753. [Google Scholar] [CrossRef] [PubMed]
- Rajkumar, S.V.; Larson, D.; Kyle, R.A. Diagnosis of smoldering multiple myeloma. N. Engl. J. Med. 2011, 365, 474–475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rajkumar, S.V.; Dimopoulos, M.A.; Palumbo, A.; Blade, J.; Merlini, G.; Mateos, M.-V.; Kumar, S.; Hillengass, J.; Kastritis, E.; Richardson, P.; et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15, e538–e548. [Google Scholar] [CrossRef]
- Mateos, M.-V.; Hernandez, M.-T.; Giraldo, P.; de la Rubia, J.; de Arriba, F.; Lopez Corral, L.; Rosinol, L.; Paiva, B.; Palomera, L.; Bargay, J.; et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 2013, 369, 438–447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mateos, M.-V.; Hernandez, M.-T.; Giraldo, P.; de la Rubia, J.; de Arriba, F.; Corral, L.L.; Rosinol, L.; Paiva, B.; Palomera, L.; Bargay, J.; et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial. Lancet. Oncol. 2016, 17, 1127–1136. [Google Scholar] [CrossRef]
- Lonial, S.; Jacobus, S.; Fonseca, R.; Weiss, M.; Kumar, S.; Orlowski, R.Z.; Kaufman, J.L.; Yacoub, A.M.; Buadi, F.K.; O’Brien, T.; et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J. Clin. Oncol. 2019. [Google Scholar] [CrossRef]
- Rasche, L.; Angtuaco, E.J.; Alpe, T.L.; Gershner, G.H.; McDonald, J.E.; Samant, R.S.; Kumar, M.; Van Hemert, R.; Epstein, J.; Deshpande, S.; et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 2018, 132, 59–66. [Google Scholar] [CrossRef] [PubMed]
- Merz, M.; Hielscher, T.; Wagner, B.; Sauer, S.; Shah, S.; Raab, M.S.; Jauch, A.; Neben, K.; Hose, D.; Egerer, G.; et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014, 2, 1902–1908. [Google Scholar] [CrossRef] [PubMed]
- Kyle, R.A.; Gertz, M.A.; Witzig, T.E.; Lust, J.A.; Lacy, M.Q.; Dispenzieri, A.; Fonseca, R.; Rajkumar, S.V.; Offord, J.R.; Larson, D.R.; et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 2003, 78, 21–33. [Google Scholar] [CrossRef]
- Caers, J.; Withofs, N.; Hillengass, J.; Simoni, P.; Zamagni, E.; Hustinx, R.; Beguin, Y. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 2014, 99, 629–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Regelink, J.C.; Minnema, M.C.; Terpos, E.; Kamphuis, M.H.; Raijmakers, P.G.; van den Bos, I.C.P.; Heggelman, B.G.F.; Nievelstein, R.J.; Otten, R.H.J.; van Lammeren-Venema, D.; et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: A systematic review. Br. J. Haematol. 2013, 162, 50–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, M.; Chung, J.; Lee, J.; Min, C.; Lee, S.; Shin, D.; Bae, S.; Hong, J.; Lee, G.; Lee, I.; et al. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. Br. J. Haematol. 2014, 165, 777–785. [Google Scholar] [CrossRef] [PubMed]
- Moulopoulos, L.A.; Gika, D.; Anagnostopoulos, A.; Delasalle, K.; Weber, D.; Alexanian, R.; Dimopoulos, M.A. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann. Oncol. 2005, 16, 1824–1828. [Google Scholar] [CrossRef]
- The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br. J. Haematol. 2003, 121, 749–757. [Google Scholar] [CrossRef] [Green Version]
- Durie, B.G.M.; Kyle, R.A.; Belch, A.; Bensinger, W.; Blade, J.; Boccadoro, M.; Child, J.A.; Comenzo, R.; Djulbegovic, B.; Fantl, D.; et al. Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol. J.Off. J. Eur. Haematol. Assoc. 2003, 4, 379–398. [Google Scholar] [CrossRef]
- Fechtner, K.; Hillengass, J.; Delorme, S.; Heiss, C.; Neben, K.; Goldschmidt, H.; Kauczor, H.-U.; Weber, M.-A. Staging monoclonal plasma cell disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology 2010, 257, 195–204. [Google Scholar] [CrossRef] [PubMed]
- Kloth, J.K.; Hillengass, J.; Listl, K.; Kilk, K.; Hielscher, T.; Landgren, O.; Delorme, S.; Goldschmidt, H.; Kauczor, H.U.; Weber, M.A. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Int. J. Cancer 2014, 135, 2380–2386. [Google Scholar] [CrossRef] [Green Version]
- Wennmann, M.; Kintzelé, L.; Piraud, M.; Menze, B.H.; Hielscher, T.; Hofmanninger, J.; Wagner, B.; Kauczor, H.-U.; Merz, M.; Hillengass, J.; et al. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget 2018, 9, 25254–25264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gleeson, T.G.; Moriarty, J.; Shortt, C.P.; Gleeson, J.P.; Fitzpatrick, P.; Byrne, B.; McHugh, J.; O’Connell, M.; O’Gorman, P.; Eustace, S.J. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2009, 38, 225–236. [Google Scholar] [CrossRef] [PubMed]
- Hillengass, J.; Moulopoulos, L.A.; Delorme, S.; Koutoulidis, V.; Mosebach, J.; Hielscher, T.; Drake, M.; Rajkumar, S.V.; Oestergaard, B.; Abildgaard, N.; et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group. Blood Cancer J. 2017, 7, e599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wolf, M.B.; Murray, F.; Kilk, K.; Hillengass, J.; Delorme, S.; Heiss, C.; Neben, K.; Goldschmidt, H.; Kauczor, H.U.; Weber, M.A. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur. J. Radiol. 2014, 83, 1222–1230. [Google Scholar] [CrossRef] [PubMed]
- Piraud, M.; Wennmann, M.; Kintzelé, L.; Hillengass, J.; Keller, U.; Langs, G.; Weber, M.-A.; Menze, B.H. Towards Quantitative Imaging Biomarkers of Tumor Dissemination: A Multi-scale Parametric Modeling of Multiple Myeloma. Med. Image Anal. 2019. [Google Scholar] [CrossRef] [PubMed]
- Baur, A.; Stabler, A.; Nagel, D.; Lamerz, R.; Bartl, R.; Hiller, E.; Wendtner, C.; Bachner, F.; Reiser, M. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002, 95, 1334–1345. [Google Scholar] [CrossRef]
- Poulton, T.B.; Murphy, W.D.; Duerk, J.L.; Chapek, C.C.; Feiglin, D.H. Bone marrow reconversion in adults who are smokers: MR Imaging findings. Am. J. Roentgenol. 1993, 161, 1217–1221. [Google Scholar] [CrossRef]
- Daldrup-Link, H.E.; Henning, T.; Link, T.M. MR imaging of therapy-induced changes of bone marrow. Eur. Radiol. 2007, 17, 743–761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gavriatopoulou, M.; Βoultadaki, A.; Koutoulidis, V.; Ntanasis-Stathopoulos, I.; Bourgioti, C.; Malandrakis, P.; Fotiou, D.; Migkou, M.; Kanellias, N.; Eleutherakis-Papaiakovou, E.; et al. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer J. 2020, 10, 93. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2020. Available online: https://www.R-project.org (accessed on 11 August 2020).
- Walker, R.; Barlogie, B.; Haessler, J.; Tricot, G.; Anaissie, E.; Shaughnessy, J.D.J.; Epstein, J.; van Hemert, R.; Erdem, E.; Hoering, A.; et al. Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. J. Clin. Oncol. 2007, 25, 1121–1128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mai, E.K.; Hielscher, T.; Kloth, J.K.; Merz, M.; Shah, S.; Raab, M.S.; Hillengass, M.; Wagner, B.; Jauch, A.; Hose, D.; et al. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 2015, 100, 818–825. [Google Scholar] [CrossRef] [Green Version]
- Mosebach, J.; Shah, S.; Delorme, S.; Hielscher, T.; Goldschmidt, H.; Schlemmer, H.-P.; Schonland, S.; Hegenbart, U.; Hillengass, J. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 2018, 103, 336–343. [Google Scholar] [CrossRef] [Green Version]
- Hillengass, J.; Ayyaz, S.; Kilk, K.; Weber, M.-A.; Hielscher, T.; Shah, R.; Hose, D.; Delorme, S.; Goldschmidt, H.; Neben, K. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012, 97, 1757–1760. [Google Scholar] [CrossRef] [PubMed]
- Hillengass, J.; Usmani, S.; Rajkumar, S.V.; Durie, B.G.M.; Mateos, M.-V.; Lonial, S.; Joao, C.; Anderson, K.C.; Garcia-Sanz, R.; Serra, E.R.; et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet. Oncol. 2019, 20, e302–e312. [Google Scholar] [CrossRef]
- Messiou, C.; Hillengass, J.; Delorme, S.; Lecouvet, F.E.; Moulopoulos, L.A.; Collins, D.J.; Blackledge, M.D.; Abildgaard, N.; Østergaard, B.; Schlemmer, H.-P.; et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 2019, 181949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
MRI-Based Biomarker | Harrelߣs c-index | Hazard Ratio | p-Value |
---|---|---|---|
Volume of the largest FL | 0.715 | 1.48 | 0.001 |
SOG of the largest FL | 0.745 | 1.97 | 0.002 |
SOG of the fastest growing FL | 0.749 | 1.99 | 0.003 |
Diffuse infiltration score | 0.673 | 1.69 | 0.014 |
Diffuse infiltration score—dynamic | 0.673 | 1.77 | <0.001 |
Multivariate Analysis | Hazard Ratio | p-Value |
---|---|---|
M-protein | 1.10 | 0.002 |
Volume of the largest FL | 1.90 | 0.009 |
M-protein | 1.11 | <0.001 |
SOG of the fastest growing FL | 2.15 | 0.012 |
M-protein | 1.15 | 0.01 |
Diffuse infiltration score | 0.86 | 0.70 |
M-protein | 1.12 | 0.02 |
Dynamic of diffuse infiltration score | 1.35 | 0.28 |
Multivariate Model | Beta | p-Value |
---|---|---|
DIS | −0.19 | <0.001 |
log_TTV | −0.05 | 0.59 |
time | −0.00 | 0.18 |
DIS | −0.18 | <0.001 |
log_SOG | 0.55 | 0.79 |
time | −0.01 | 0.14 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wennmann, M.; Hielscher, T.; Kintzelé, L.; Menze, B.H.; Langs, G.; Merz, M.; Sauer, S.; Kauczor, H.-U.; Schlemmer, H.-P.; Delorme, S.; et al. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers 2021, 13, 961. https://doi.org/10.3390/cancers13050961
Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor H-U, Schlemmer H-P, Delorme S, et al. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers. 2021; 13(5):961. https://doi.org/10.3390/cancers13050961
Chicago/Turabian StyleWennmann, Markus, Thomas Hielscher, Laurent Kintzelé, Bjoern H. Menze, Georg Langs, Maximilian Merz, Sandra Sauer, Hans-Ulrich Kauczor, Heinz-Peter Schlemmer, Stefan Delorme, and et al. 2021. "Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns" Cancers 13, no. 5: 961. https://doi.org/10.3390/cancers13050961